Alembic Pharma Gains USFDA Tentative Approval for Darolutamide Tablets in U.S. Oncology Market

Alembic Pharmaceuticals has cleared a significant regulatory checkpoint with a USFDA tentative approval for Darolutamide Tablets, 300 mg, a generic entry into a U.S. market estimated at $3.155 billion. For QA directors and regulatory leads tracking the company's U.S. portfolio, the approval signals manufacturing and dossier readiness, while the conversion to final approval remains contingent on patent or exclusivity expiry.

Tentative approval under 21 CFR Part 314 confirms that FDA has found the ANDA scientifically and technically approvable, GMP compliance, bioequivalence data, and labeling reviewed and accepted, but the product cannot enter commerce until applicable Orange Book-listed patents or exclusivity periods lapse. For plant heads, this is the interval to stress-test commercial-scale process validation, batch release protocols, and supply-chain readiness so that conversion to final approval triggers an immediate launch posture rather than a remediation cycle.

Darolutamide, marketed as Nubeqa by Bayer, is indicated for non-metastatic castration-resistant prostate cancer and, more recently, metastatic castration-sensitive prostate cancer, a therapeutic area where demand trajectories are well-established and generic competition is expected to be competitive on entry. A $3.155 billion reference market means even a modest market-share capture carries material volume implications for Alembic's sterile and solid-dose manufacturing network.

Alembic has been systematically expanding its U.S. generic oncology pipeline, and this tentative approval adds a high-value asset to that queue. Regulatory affairs leads should note that the ANDA's approvability status also reflects the agency's current review posture on oncology generics, a category where ICH Q10-aligned pharmaceutical quality systems and robust CAPA documentation have become baseline expectations during pre-approval inspections.

The measurable outcome to track is the patent expiry date for Nubeqa's Orange Book listings, which will set the earliest possible conversion date and define the competitive launch window for Alembic and any other tentatively approved applicants.

Source: Media4Growth via Indian Pharma Post, 14 May 2026.